Under a tenth of individuals who could benefit from obesity jabs like Wegovy are able to get them, caution the World Health Organization as it publishes its inaugural advice on the drugs.
With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for more widespread and fairer access to these injectable treatments.
Per forecasts, over two billion will be obese by 2030 without intervention.
"Our latest guidelines affirms that excess weight is a lifelong illness that can be treated with holistic and continuous care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major barriers to widespread access to the injections that can aid individuals in losing substantial body mass, says the organization.
GLP-1 Therapy Shortage
Even under the present most optimistic outlook, the production of GLP-1 therapies could only cover approximately 100 million people – less than 10% of those who need them, per the health organization.
The guideline urges countries and companies to widen availability, by measures including voluntary licensing.
A patent on a key compound – the primary component of a leading brand – is set to lapse in multiple nations in 2026.
The Way Obesity Jabs Operate
These medications imitate a body's own hormone to reduce digestion speed, suppress the appetite and boost satiety so individuals reduce food intake.
Individuals typically see weight reduction after several weeks of starting on the weekly injections.
Research indicates patients may regain a significant portion after a year of stopping the drug, as their usual hunger resume.
To be above a healthy weight raises your risk for contracting diseases, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity concerns people in countries worldwide and was linked to millions of deaths worldwide in 2024, per the WHO.
